Gene therapy
AssigneeThe University of Manchester
InventorsBrian Bigger, Hélène Gleitz
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe University of Manchester
InventorsBrian Bigger, Hélène Gleitz
Estimating the term…
The present invention relates generally to polypeptides or nucleic acids for use in the treatment, management, retardation of progression or normalisation of development of an iduronate-2-sulfatase (IDS) deficiency and/or Mucopolysaccharidosis type II (MPS II) in an individual, wherein the polypeptides comprise iduronate-2-sulfatase (IDS) tethered to a tandem repeat of Apolipoprotein E (ApoEII) or the nucleic acids comprise an iduronate-2-sulfatase (IDS) gene sequence tethered to a tandem repeat of the Apolipoprotein E (ApoEII) gene sequence. The invention also relates to haematopoietic stem and progenitor cells (HSPCs) transduced by such nucleic acids for use in therapies.
A nucleic acid comprising an iduronate-2-sulfatase (IDS) gene sequence and a repeat of the Apolipoprotein E (ApoEII) gene sequence.
(canceled)
A composition comprising:
(canceled)
A method for delivering a deficient iduronate-2-sulfatase (IDS) protein into the brain across the blood brain barrier in an individual suffering from a condition resulting from the deficiency in the protein, the composition comprising a viral vector comprising the gene sequence coding for the deficient protein tethered to a tandem repeat of the Apolipoprotein E (ApoEII) gene sequence, wherein the vector is transduced, ex vivo, with a population of haematopoietic stem and progenitor cells (HSPCs) and the transduced HSPCs administered to the individual where they express higher physiological levels of the deficient protein which are sufficient to cross the blood brain barrier.
-25. (canceled)
A combination of a nucleic acid comprising an iduronate-2-sulfatase (IDS) gene sequence and a repeat of the Apolipoprotein E (ApoEII) gene sequence and one or more haematopoietic stem and progenitor cells (HSPCs), wherein the nucleic acid is capable of transducing the HSPCs.
Dependencies are inferred from the claim text.